Evidence map›Paper›PMID 41420177›Full record

ReviewJournal of translational medicine2025

Therapeutic potential of curcumin in ophthalmic diseases: mechanisms and clinical applications.

Kangning Wang, Tian Tian, Zijian Chen, Xue He, Yi Xiang, Guojin Zuo, Shizhou Cheng

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Neuroprotection in Early Diabetic Retinal Disease Using Eyedrop Delivery.International journal of molecular sciences · 2026
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kangning Wang *Department of Ophthalmology, The First Affiliated Hospital, Yangtze University, Jingzhou, 434000, China.
Tian Tian *Department of Ophthalmology, The First Affiliated Hospital, Yangtze University, Jingzhou, 434000, China.
Zijian ChenDepartment of Ophthalmology, The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330000, China.
Xue HeDepartment of Ophthalmology, The First Affiliated Hospital, Yangtze University, Jingzhou, 434000, China.
Yi XiangDepartment of Ophthalmology, The First Affiliated Hospital, Yangtze University, Jingzhou, 434000, China.
Guojin ZuoDepartment of Ophthalmology, The First Affiliated Hospital, Yangtze University, Jingzhou, 434000, China. 18163139787@163.com.
Shizhou ChengDepartment of Ophthalmology, The First Affiliated Hospital, Yangtze University, Jingzhou, 434000, China. shizhou_Cheng@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ocular diseases impacting both the front and back segments of the eye are major contributors to worldwide vision loss. Curcumin, extracted from the rhizome of Curcuma longa, is a lipophilic polyphenol whose broad pharmacologic profile, including antioxidant, anti-inflammatory, antimutagenic, antimicrobial, and antineoplastic, renders it an attractive prospect for ocular therapeutics. However, much of the existing research primarily focuses on the general mechanisms of curcumin in the human body, with a lack of comprehensive reviews specifically addressing its mechanisms in ophthalmic diseases. Therefore, this review aims to explore curcumin's therapeutic potential in ophthalmic disorders and examine its mechanisms of action in terms of its anti-inflammatory, antioxidant, anti-angiogenic, neuroprotective roles, and antibacterial effects. The influence of curcumin on a range of ocular diseases, including age-related macular degeneration, diabetic retinopathy, glaucoma, cataracts, dry eye disease, pterygium, and uveitis, was also discussed. An analysis of preclinical and clinical studies conducted over the past 5 years suggested that curcumin holds promise as a therapeutic agent for various eye disorders. Furthermore, the review addressed the challenges faced in the clinical translation of curcumin in ophthalmology, such as issues related to dosage, formulation, and long-term safety. Despite curcumin's promising efficacy in preclinical models, several hurdles remain in its clinical application, highlighting the need for further research to facilitate its broader use in ophthalmic treatment.

Indexed as

CurcuminEye DiseasesAnimalsAntioxidantsClinical Trials as TopicHumansAntioxidantsCurcuminAnti-angiogenicAnti-inflammatoryAntioxidantCurcuminNeuroprotectiveOphthalmic diseases

Identifiers

PMID41420177
PMCPMC12715913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.